Abstract：
BACKGROUND: This exploratory study investigated cerebrospinal fluid (CSF) synaptic protein biomarkers in bipolar disorder (BD), aiming to highlight the neurobiological basis of the disorder. With shared cognitive impairment features between BD and Alzheimer\'s disease, and considering increased dementia risk in BD patients, the study explores potential connections.
METHODS: Fifty-nine well-characterized patients with BD and thirty-seven healthy control individuals were examined and followed for one year. Synaptic proteins encompassing neuronal pentraxins (NPTX)1, NPTX2, and NPTX-receptor, 14-3-3 protein family epsilon, and zeta/delta, activating protein-2 complex subunit beta, synucleins beta-synuclein and gamma-synuclein, complexin-2, phosphatidylethanolamine-binding protein 1, rab GDP dissociation inhibitor alpha, and syntaxins 1B and 7 were measured in CSF using a microflow liquid chromatography-mass spectrometric multiple reaction monitoring set-up. Biomarker levels were compared between BD and HC and in BD before, during, and after mood episodes.
RESULTS: The synaptic proteins revealed no statistically significant differences between BD and HC, neither at baseline, one-year follow-up, or in terms of changes from baseline to follow-up. Moreover, the CSF synaptic protein levels in patients with BD were unaltered compared to baseline when they stabilized in euthymia following an affective episode and at one-year follow-up.
CONCLUSIONS: It is uncertain what the CSF biomarker concentrations reflect since we yet do not know the mechanisms of release of these proteins, and we are uncertain of what increased or decreased levels reflect.
CONCLUSIONS: This first-ever investigation of a panel of CSF protein biomarkers of synaptic dysfunction in patients with BD and HC individuals found no statistically significant differences cross-sectionally or longitudinally.
METHODS: Fifty-nine well-characterized patients with BD and thirty-seven healthy control individuals were examined and followed for one year. Synaptic proteins encompassing neuronal pentraxins (NPTX)1, NPTX2, and NPTX-receptor, 14-3-3 protein family epsilon, and zeta/delta, activating protein-2 complex subunit beta, synucleins beta-synuclein and gamma-synuclein, complexin-2, phosphatidylethanolamine-binding protein 1, rab GDP dissociation inhibitor alpha, and syntaxins 1B and 7 were measured in CSF using a microflow liquid chromatography-mass spectrometric multiple reaction monitoring set-up. Biomarker levels were compared between BD and HC and in BD before, during, and after mood episodes.
RESULTS: The synaptic proteins revealed no statistically significant differences between BD and HC, neither at baseline, one-year follow-up, or in terms of changes from baseline to follow-up. Moreover, the CSF synaptic protein levels in patients with BD were unaltered compared to baseline when they stabilized in euthymia following an affective episode and at one-year follow-up.
CONCLUSIONS: It is uncertain what the CSF biomarker concentrations reflect since we yet do not know the mechanisms of release of these proteins, and we are uncertain of what increased or decreased levels reflect.
CONCLUSIONS: This first-ever investigation of a panel of CSF protein biomarkers of synaptic dysfunction in patients with BD and HC individuals found no statistically significant differences cross-sectionally or longitudinally.
摘要：
背景：这项探索性研究调查了双相情感障碍（BD）的脑脊液（CSF）突触蛋白生物标志物，旨在突出该疾病的神经生物学基础。BD和阿尔茨海默病具有共同的认知障碍特征，考虑到BD患者痴呆风险增加，这项研究探索了潜在的联系。
方法：对59名具有良好特征的BD患者和37名健康对照者进行了检查并随访一年。包含神经元五聚素（NPTX）1，NPTX2和NPTX受体的突触蛋白，14-3-3蛋白家族ε，和zeta/delta，激活蛋白-2复合物亚基β，突触核蛋白β-突触核蛋白和γ-突触核蛋白，complexin-2，磷脂酰乙醇胺结合蛋白1，rabGDP解离抑制剂α，使用微流液相色谱-质谱多反应监测装置在CSF中测量了突触素1B和7。比较BD和HC之间以及BD之前的生物标志物水平，during,在情绪发作之后。
结果：突触蛋白显示BD和HC之间没有统计学上的显着差异，无论是在基线，一年的随访,或从基线到后续行动的变化。此外，与基线相比,BD患者的CSF突触蛋白水平在情感发作后和1年随访时稳定在正常状态时没有改变.
结论：由于我们还不知道这些蛋白质的释放机制，因此尚不确定CSF生物标志物浓度反映了什么。我们不确定水平的增加或减少反映了什么。
结论：首次对一组BD和HC患者的突触功能障碍的CSF蛋白生物标志物进行研究发现，在横截面或纵向上没有统计学上的显著差异。
方法：对59名具有良好特征的BD患者和37名健康对照者进行了检查并随访一年。包含神经元五聚素（NPTX）1，NPTX2和NPTX受体的突触蛋白，14-3-3蛋白家族ε，和zeta/delta，激活蛋白-2复合物亚基β，突触核蛋白β-突触核蛋白和γ-突触核蛋白，complexin-2，磷脂酰乙醇胺结合蛋白1，rabGDP解离抑制剂α，使用微流液相色谱-质谱多反应监测装置在CSF中测量了突触素1B和7。比较BD和HC之间以及BD之前的生物标志物水平，during,在情绪发作之后。
结果：突触蛋白显示BD和HC之间没有统计学上的显着差异，无论是在基线，一年的随访,或从基线到后续行动的变化。此外，与基线相比,BD患者的CSF突触蛋白水平在情感发作后和1年随访时稳定在正常状态时没有改变.
结论：由于我们还不知道这些蛋白质的释放机制，因此尚不确定CSF生物标志物浓度反映了什么。我们不确定水平的增加或减少反映了什么。
结论：首次对一组BD和HC患者的突触功能障碍的CSF蛋白生物标志物进行研究发现，在横截面或纵向上没有统计学上的显著差异。
